Louisa C. Dunmall

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

Correction: A novel oncolytic Vaccinia virus armed with IL-12 augments antitumor immune responses leading to durable regression in murine models of lung cancer.

Correction: A novel oncolytic Vaccinia virus armed with IL-12 augments antitumor immune responses leading to durable regression in murine models of lung cancer.

Journal: Frontiers in immunology
Published: February 16, 2026

The oncolytic adenovirus Ad-TD-nsIL12 in primary or progressive pediatric IDH wild-type diffuse intrinsic pontine glioma results of two phase I clinical trials.

The oncolytic adenovirus Ad-TD-nsIL12 in primary or progressive pediatric IDH wild-type diffuse intrinsic pontine glioma results of two phase I clinical trials.

Journal: Nature communications
Published: June 04, 2025

Ectopic HLA-II Expression in ESCC: Exploration of Its Relationship with Neoantigen Burden and Patient Survival.

Ectopic HLA-II Expression in ESCC: Exploration of Its Relationship with Neoantigen Burden and Patient Survival.

Journal: Cells
Published: May 13, 2025

A novel oncolytic Vaccinia virus armed with IL-12 augments antitumor immune responses leading to durable regression in murine models of lung cancer.

A novel oncolytic Vaccinia virus armed with IL-12 augments antitumor immune responses leading to durable regression in murine models of lung cancer.

Journal: Frontiers in immunology
Published: September 07, 2024

Treatment of intracranial inflammatory myofibroblastic tumor with PD-L1 inhibitor and novel oncolytic adenovirus Ad-TD-nsIL12: a case report and literature review.

Treatment of intracranial inflammatory myofibroblastic tumor with PD-L1 inhibitor and novel oncolytic adenovirus Ad-TD-nsIL12: a case report and literature review.

Journal: Frontiers in immunology
Published: May 07, 2024

Genomic-transcriptomic analysis identifies the Syrian hamster as a superior animal model for human diseases.

Genomic-transcriptomic analysis identifies the Syrian hamster as a superior animal model for human diseases.

Journal: BMC genomics
Published: February 16, 2024

Non-secreting IL12 expressing oncolytic adenovirus Ad-TD-nsIL12 in recurrent high-grade glioma: a phase I trial.

Non-secreting IL12 expressing oncolytic adenovirus Ad-TD-nsIL12 in recurrent high-grade glioma: a phase I trial.

Journal: Nature communications
Published: December 11, 2023

The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors.

The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors.

Journal: Cancer letters
Published: October 27, 2023

The capability of heterogeneous γδ T cells in cancer treatment.

The capability of heterogeneous γδ T cells in cancer treatment.

Journal: Frontiers in immunology
Published: August 30, 2023

Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCL.

Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCL.

Journal: Molecular therapy oncolytics
Published: March 28, 2023

Syrian hamster as an ideal animal model for evaluation of cancer immunotherapy.

Syrian hamster as an ideal animal model for evaluation of cancer immunotherapy.

Journal: Frontiers in immunology
Published: December 18, 2022

MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy.

MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy.

Journal: Oncoimmunology
Published: June 03, 2022
Showing 1-12 of 18

Last Updated: 09/26/2026